Mean arterial pressure (mm Hg) | minute −5 | minute 6 | minute 40 |
BDL | |||
Amiloride 0.1 mg/kg b.w. | 109±12 | 115±14 | 114±12 |
Amiloride 0.25 mg/kg b.w. | 117±15 | 110±12 | 117±14 |
Amiloride 0.5 mg/kg b.w. | 103±15 | 105±10 | 107±11 |
Canrenoate 2.5 mg/kg b.w. | 105±14 | 98±12 | 104±10 |
Canrenoate 5 mg/kg b.w. | 108±12 | 105±14 | 108±12 |
Canrenoate 10 mg/kg b.w. | 102±14 | 110±12 | 112±14 |
Zymosan | 109±12 | 84±15 | 67±12† |
Zymosan + amiloride 0.25 mg/kg b.w. | 104±15 | 81±14 | 64±12† |
TAA | |||
Zymosan | 124±12 | 115±11 | 85±9* |
Zymosan + canrenoate pre-treatment | 121±14 | 110±8 | 78±7* |
Zymosan + amiloride pre-treatment | 115±11 | 97±8 | 75±5* |
The mean arterial pressure did not differ between bile duct ligated (BDL) and thioacetamide administered animals (TAA). Mean arterial pressure decreased by Kupffer cell activation via zymosan (150 μg/ml) from minute 0 to 6 in the BDL animals with or without immediate amiloride treatement (*p<0.05). Mean arterial pressure also decreased in the TAA animals by zymosan (150 μg/ml) administration (†p<0.05), but the mean arterial pressure was not influenced by canrenoate (10 mg/kg b.w.) or amiloride (0.1 mg/kg b.w.) pre-treatment